165 related articles for article (PubMed ID: 6809014)
1. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
Brock N; Stekar J
Arzneimittelforschung; 1982; 32(5):486-7. PubMed ID: 6809014
[TBL] [Abstract][Full Text] [Related]
2. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
Brock N; Pohl J
IARC Sci Publ; 1986; (78):269-79. PubMed ID: 3108156
[TBL] [Abstract][Full Text] [Related]
3. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).
Habs MR; Schmähl D
Cancer; 1983 Feb; 51(4):606-9. PubMed ID: 6401591
[TBL] [Abstract][Full Text] [Related]
4. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
Brock N; Pohl J; Stekar J
J Cancer Res Clin Oncol; 1981; 100(3):311-20. PubMed ID: 6792207
[TBL] [Abstract][Full Text] [Related]
5. Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.
Mohrmann M; Ansorge S; Schönfeld B; Brandis M
Pediatr Nephrol; 1994 Aug; 8(4):458-65. PubMed ID: 7524598
[TBL] [Abstract][Full Text] [Related]
6. [Antidote against the urotoxic effects of the oxazaphorine derivatives cyclophosphamide, ifosfamide and trofosfamide].
Brock N; Stekar J; Pohl J
Naturwissenschaften; 1979 Jan; 66(1):60-1. PubMed ID: 106307
[No Abstract] [Full Text] [Related]
7. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
[TBL] [Abstract][Full Text] [Related]
8. The interactions of mesna and dimesna with the sulfate exchange in human red blood cells.
Reuther H; Kohl M; Wildenauer DB
Arzneimittelforschung; 1986 Apr; 36(4):763-5. PubMed ID: 3087373
[TBL] [Abstract][Full Text] [Related]
9. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).
Brock N; Pohl J; Stekar J; Scheef W
Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1377-87. PubMed ID: 6819957
[TBL] [Abstract][Full Text] [Related]
10. [Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences].
Schmähl D; Habs M; Tacchi AM
Urologe A; 1984 Sep; 23(5):291-6. PubMed ID: 6438859
[TBL] [Abstract][Full Text] [Related]
11. Effect of the uroprotector sodium 2-mercaptoethane sulfonate (Mesna) on the proliferation of the bladder urothelium in the rat after administration of cyclophosphamide.
Kunze E; Köhnecke B; Engelhardt W; Steinröder H; Brock N; Pohl J
Urol Int; 1984; 39(2):61-7. PubMed ID: 6426112
[TBL] [Abstract][Full Text] [Related]
12. Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity.
Hilgard P; Burkert H
Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1451-2. PubMed ID: 6437825
[No Abstract] [Full Text] [Related]
13. Renal transport and disposition of Na-2-mercaptoethane sulfonate disulfide (dimesna) in the rat.
Ormstad K; Uehara N
FEBS Lett; 1982 Dec; 150(2):354-8. PubMed ID: 6819161
[TBL] [Abstract][Full Text] [Related]
14. Does 2-mercaptoethane sulphonate (mesna) prevent cyclophosphamide and azathioprine induced immunosuppression? In vitro studies.
Al-Safi SA; Maddocks JL
Br J Clin Pharmacol; 1986 Mar; 21(3):267-70. PubMed ID: 2938613
[TBL] [Abstract][Full Text] [Related]
15. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
Brock N
Recent Results Cancer Res; 1980; 74():270-8. PubMed ID: 6777836
[TBL] [Abstract][Full Text] [Related]
16. The prevention of cyclophosphamide-induced bladder swelling in the rat by I.V. administration of sodium-2-mercaptoethane sulfonate.
Kedar A; Simpson CL; Williams P; Moore R; Tritsch G; Murphy GP
Res Commun Chem Pathol Pharmacol; 1980 Aug; 29(2):339-48. PubMed ID: 6774389
[TBL] [Abstract][Full Text] [Related]
17. Reduction of dimesna to mesna by the isolated perfused rat liver.
Goren MP; Hsu LC; Li JT
Cancer Res; 1998 Oct; 58(19):4358-62. PubMed ID: 9766664
[TBL] [Abstract][Full Text] [Related]
18. Proceedings of a symposium on ifosfamide (Mitoxana; Holoxan) and Mesna (Uromitexan). Coventry, U.K., 16-18 March 1983.
Cancer Treat Rev; 1983 Sep; 10 Suppl A():1-192. PubMed ID: 6414687
[No Abstract] [Full Text] [Related]
19. The fate of [14C]-mesna in the rat.
Shaw IC; Graham MI; Jones MS
Arzneimittelforschung; 1986 Mar; 36(3):487-9. PubMed ID: 3085684
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability of orally administered mesna.
Burkert H; Lücker PW; Wetzelsberger N; Breuel HP
Arzneimittelforschung; 1984; 34(11):1597-600. PubMed ID: 6441581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]